학술논문

Prognostic value of inflammatory markers in patients presenting with acute coronary syndrome.
Document Type
Article
Source
Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research). 2021, Vol. 12 Issue 1, p151-157. 7p.
Subject
*ACUTE coronary syndrome
*PROGNOSIS
*CORONARY artery disease
*DISEASE risk factors
*NEUTROPHIL lymphocyte ratio
Language
ISSN
0975-3583
Abstract
Objective: The objective of the study is to study the use of IL6, IL10, TNF, CRP, neutrophil-lymphocyte ratio (NLR) as a prognostic biomarker for patients presenting with the acute coronary syndrome. Background: ACS is the most common cause of death worldwide, but mortality due to Coronary artery disease slowly came down and reached a plateau. ACS occurs in response to inflammation, plaque rupture and subsequent thrombosis, progressive mechanical obstruction, and dynamic obstruction. Methods: It is a Prospective study of 100 patients, both Male and Female with ACS admitted to the SJICR with ACS, were subjected to the Full clinical evaluation including history and physical examination with particular emphasis on risk factors. Results: Most of the patients studied were STEMI; only seven patients of NSTEMI were included. The male to female ratio was 3.55. The most commonly associated risk factors were smoking, diabetes mellitus, hypertension. STEMI patients had a shorter window period compared to NSTEMI. The mean duration of hospitalization was three days. Inflammatory markers were compared across various TIMI risk scores. When compared to the TIMI score of <4 to >4, HsCRP shows a significant correlation. While other inflammatory markers showed higher values with higher TIMI scores but P value was not significant. Conclusion: NLR, HsCRP, IL6, IL10 are significantly associated with TIMI, GRACE, KILLIP risk scoring systems. Inflammatory markers except TNF, shows the correlation with mortality, morbidity, the extent of CAD. These markers explain other domain of pathogenesis in ACS which is a potential target for newer therapeutics. [ABSTRACT FROM AUTHOR]